This Article  • Full text PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in JAMA  Social Bookmarking   What's this?

Peter S. Arno, PhD; Douglas Shenson, MD, MPH
Montefiore Medical Center Albert Einstein College of Medicine New York, NY

Naomi F. Siegel, MSPH
University of North Carolina Chapel Hill

Pat Franks; Philip R. Lee, MD
University of California San Francisco

JAMA. 1990;263(8):1068.

	Since this article does not have an abstract, we have provided the first 150 words of the full text PDF and any section headings.

In Reply.—

We appreciate the thoughtful responses of Drs Cheung and Sacks and Dr Harris and Mr Rattner to our article on the economic and policy implications of early intervention in HIV disease. The study was conceived and researched in the year prior to the release of data from national clinical trials, which now indicate that low-dose zidovudine therapy can be effective in slowing progression from asyptomatic HIV disease to AIDS. This breakthrough significantly enhances the importance and feasibility of providing successful early intervention services.

We estimate in our article the economic magnitude of providing care to 25%, 50%, and 100% of the HIV-infected populations in New York, NY, San Francisco, Calif, and the United States. Our cost figures reflect the best available epidemiologic and treatment data, and our midrange estimates fall between those suggested by Drs Cheung and Sacks and Dr Harris and Mr Rattner.

This costing model . . . [Full Text PDF of this Article]

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?